Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide - PubMed (original) (raw)
. 2005 Apr 1;105(7):2862-8.
doi: 10.1182/blood-2004-06-2410. Epub 2004 Dec 9.
Affiliations
- PMID: 15591121
- DOI: 10.1182/blood-2004-06-2410
Free article
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
M E Christine Lutsiak et al. Blood. 2005.
Free article
Abstract
Regulatory T cells (T(REGs)) control the key aspects of tolerance and play a role in the lack of antitumor immune responses. Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Although a previous study demonstrated that CY reduces the number of T(REGs), the mechanism involved in this process has yet to be defined. In this report, it is established that low-dose CY not only decreases cell number but leads to decreased functionality of T(REGs). CY treatment enhances apoptosis and decreases homeostatic proliferation of these cells. Expression of GITR and FoxP3, which are involved in the suppressive activity of T(REGs), is down-regulated after CY administration, though the level of expression varies depending on the time studied. This is the first report demonstrating that CY, in addition to decreasing cell number, inhibits the suppressive capability of T(REGs). The relevance of the loss of suppressor functionality and the changes in gene expression are further discussed.
Similar articles
- Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity.
Ikezawa Y, Nakazawa M, Tamura C, Takahashi K, Minami M, Ikezawa Z. Ikezawa Y, et al. J Dermatol Sci. 2005 Aug;39(2):105-12. doi: 10.1016/j.jdermsci.2005.02.002. J Dermatol Sci. 2005. PMID: 15899580 - Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S, Hallek M, Schultze JL. Beyer M, et al. Blood. 2005 Sep 15;106(6):2018-25. doi: 10.1182/blood-2005-02-0642. Epub 2005 May 24. Blood. 2005. PMID: 15914560 - The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.
Li L, Chao QG, Ping LZ, Xue C, Xia ZY, Qian D, Shi-ang H. Li L, et al. Cancer Biother Radiopharm. 2009 Jun;24(3):357-67. doi: 10.1089/cbr.2008.0612. Cancer Biother Radiopharm. 2009. PMID: 19538059 - Control of immune homeostasis by naturally arising regulatory CD4+ T cells.
Gavin M, Rudensky A. Gavin M, et al. Curr Opin Immunol. 2003 Dec;15(6):690-6. doi: 10.1016/j.coi.2003.09.011. Curr Opin Immunol. 2003. PMID: 14630204 Review.
Cited by
- The future of cancer treatment: combining radiotherapy with immunotherapy.
Dagar G, Gupta A, Shankar A, Chauhan R, Macha MA, Bhat AA, Das D, Goyal R, Bhoriwal S, Pandita RK, Prasad CP, Sarkar PS, Pandita TK, Singh M. Dagar G, et al. Front Mol Biosci. 2024 Jul 9;11:1409300. doi: 10.3389/fmolb.2024.1409300. eCollection 2024. Front Mol Biosci. 2024. PMID: 39044839 Free PMC article. Review. - The breast cancer tumor microenvironment and precision medicine: immunogenicity and conditions favoring response to immunotherapy.
Nicolini A, Ferrari P, Silvestri R, Gemignani F. Nicolini A, et al. J Natl Cancer Cent. 2024 Jan 26;4(1):14-24. doi: 10.1016/j.jncc.2024.01.004. eCollection 2024 Mar. J Natl Cancer Cent. 2024. PMID: 39036381 Free PMC article. Review. - Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy.
Mpekris F, Panagi M, Charalambous A, Voutouri C, Stylianopoulos T. Mpekris F, et al. Cell Rep Med. 2024 Jul 16;5(7):101626. doi: 10.1016/j.xcrm.2024.101626. Epub 2024 Jun 28. Cell Rep Med. 2024. PMID: 38944037 Free PMC article. Review. - Immune regulation and therapeutic application of T regulatory cells in liver diseases.
Ajith A, Merimi M, Arki MK, Hossein-Khannazer N, Najar M, Vosough M, Sokal EM, Najimi M. Ajith A, et al. Front Immunol. 2024 Mar 20;15:1371089. doi: 10.3389/fimmu.2024.1371089. eCollection 2024. Front Immunol. 2024. PMID: 38571964 Free PMC article. Review. - Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.
Jan N, Sofi S, Qayoom H, Shabir A, Haq BU, Macha MA, Almilaibary A, Mir MA. Jan N, et al. Heliyon. 2024 Jan 14;10(3):e24670. doi: 10.1016/j.heliyon.2024.e24670. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38314272 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials